These findings suggest that patients with difficult-to-treat AD may benefit from therapy with abrocitinib, potentially due to its high selectivity for JAK1, which may explain its efficacy where other JAK inhibitors have failed. This evidence concerns the gene JAK1 and Alzheimer disease.